NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Stock Information for Neuropace Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Neuropace Inc.

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace Announces FDA Approval of ECoG Assistant(TM), Advancing AI-Driven Epilepsy Care
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace to Present at the Leerink Global Healthcare Conference
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.